Insiders BridgeBio Pharma, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
23.38 ^USD	+1.65%		-15.32%	-42.09%

06-18	BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial	MT
06-18	BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)	CI

Bridgebio Pharma Insider Sold Shares Worth $4,206,000, According to a Recent SEC Filing	12-28	MT
Bridgebio Pharma Insider Sold Shares Worth $1,500,038, According to a Recent SEC Filing	11-20	MT
Bridgebio Pharma Insider Sold Shares Worth $660,059, According to a Recent SEC Filing	11-20	MT
Insider Sell: Bridgebio Pharma	23-08-18	MT
Insider Sell: Bridgebio Pharma	23-08-18	MT
Insider Sell: Bridgebio Pharma	23-05-18	MT
Insider Sell: Bridgebio Pharma	23-05-18	MT
Insider Sell: Bridgebio Pharma	23-05-05	MT
Insider Sell: Bridgebio Pharma	23-05-05	MT
Insider Sell: BridgeBio Pharma	23-03-06	MT
BridgeBio Pharma, Inc. Announces Board and Committee Changes	23-02-23	CI
Insider Sell: BridgeBio Pharma	23-02-07	MT
BridgeBio Pharma Executive to Join Atai Life Sciences as CFO	22-06-17	MT
Insider Buy: Bridgebio Pharma	22-01-04	MT
Bridgebio Pharma, Inc. Appoints Hannah Valantine to Its Board of Directors	21-10-25	CI
BridgeBio Pharma, Inc Announces Board Appointments	21-08-24	CI
Bridgebio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to Its Board of Directors	21-08-18	CI
Biomea Fusion : Names Franco Valle Finance Chief	21-06-29	MT
BridgeBio Pharma : Principal Accounting Officer Yi Ching Yau Steps Down	21-01-04	MT
BridgeBio Pharma, Inc. Announces Executive Changes	21-01-04	CI

No results for this search